Better U and Evernow have launched a nationwide telehealth partnership combining menopause and hormone expertise with integrative psychiatry, addressing perimenopausal mood, sleep and cognitive complaints as hormonally driven rather than purely psychiatric. The model includes screened, off-label at-home ketamine for treatment-resistant depression or anxiety, though no outcome data has been published. The clinical rationale rests on estrogen's modulation of serotonin and dopamine and allopregnanolone's action at GABA receptors.
Key Points
- Menopause specialists and psychiatrists combined in one nationwide telehealth pathway
- Estrogen and allopregnanolone shifts drive anxiety, insomnia, cognitive complaints
- At-home ketamine offered off-label; no outcome data released
Longevity Analysis
Misattributing perimenopausal symptoms to stress or ageing delays intervention during a window when hormonal, neurological and cardiometabolic trajectories are still modifiable. Correct interpretation of the signal — recognizing that disrupted sleep, mood instability and cognitive slowing often trace back to fluctuating steroid hormones acting on serotonin, dopamine and GABA pathways — determines whether treatment targets the mechanism or the surface complaint. Access models like this expand reach, but absent published outcomes they remain delivery infrastructure rather than demonstrated benefit, and the wider metabolic and vascular dimensions of the transition sit outside their current scope.
Original published by Longevity.Technology, by Kyle Umipig.